The Chagas Disease (American Trypanosomiasis) drugs in development market research report provides comprehensive information on the therapeutics under development for Chagas Disease (American Trypanosomiasis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Chagas Disease (American Trypanosomiasis). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Chagas Disease (American Trypanosomiasis) and features dormant and discontinued products.
GlobalData tracks 44 drugs in development for Chagas Disease (American Trypanosomiasis) by 32 companies/universities/institutes. The top development phase for Chagas Disease (American Trypanosomiasis) is preclinical with 31 drugs in that stage. The Chagas Disease (American Trypanosomiasis) pipeline has 21 drugs in development by companies and 23 by universities/ institutes. Some of the companies in the Chagas Disease (American Trypanosomiasis) pipeline products market are: Drugs for Neglected Diseases initiative, Novartis and University of California San Francisco.
The key targets in the Chagas Disease (American Trypanosomiasis) pipeline products market include Cruzipain (Major Cysteine Proteinase or Cruzain or EC 3.4.22.51), Lanosterol 14 Alpha Demethylase (Sterol 14 Alpha Demethylase or Cytochrome P450 14DM or Cytochrome P450LI or Cytochrome P450 51A1 or CYPLI or CYP51A1 or EC 1.14.14.154), and DNA.
The key mechanisms of action in the Chagas Disease (American Trypanosomiasis) pipeline product include Cruzipain (Major Cysteine Proteinase or Cruzain or EC 3.4.22.51) Inhibitor with five drugs in Preclinical. The Chagas Disease (American Trypanosomiasis) pipeline products include two routes of administration with the top ROA being Oral and six key molecule types in the Chagas Disease (American Trypanosomiasis) pipeline products market including Small Molecule, and Vaccine.
Chagas Disease (American Trypanosomiasis) overview
Chagas disease, or American trypanosomiasis is a vector-borne anthropozoonosis caused by the protozoan parasite Trypanosoma cruzi. Symptoms include swelling at the infection site, fever, fatigue, body aches, loss of appetite, nausea, diarrhea or vomiting, and swollen glands. Treatment includes antiparasitic medications.
For a complete picture of Chagas Disease (American Trypanosomiasis)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
